With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

 

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link

 

The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:

§  Therapeutic Area 

• Autoimmune Disorders
• Eye Disorders
• Genetic Disorders
• Hematological Malignancies
• Infectious Diseases
• Inflammatory Disorders
• Skin Disorders

 

§  Mechanism of Action

• Cytokines Retargeting / Neutralization
• Dual Ligands Blocking
• T-cell Retargeting / Activation
• Others

 

§  Target Antigens

• CD3 x CD19
• CD30 x CD16A
• Factor IXa x Factor X
• IL-1α x IL-1β
• IL-13 x IL-4
• IL-17A x Albumin
• IL-17A x IL-17F
• Psl x PcrV
• VEGF-A x ANG2
• Others

 

§  Antibody Formats

• Asymmetric
• Fragments
• Symmetric
• Others

 

§  Key Geographical Regions 

• North America
• Europe
• Asia-Pacific

 

The Bispecific Antibody Therapeutics Market (4^th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

§  Amgen

§  Ablynx

§  AbbVie

§  Affibody

§  Affimed

§  Alphamab

§  AstraZeneca

§  Avillion

§  Chugai Pharmaceuticals

§  Eddingpharm

§  GSK

§  Merck

§  Merus

§  Roche

§  Regeneron Pharmaceuticals

§  Taisho Pharmaceuticals

§  Zymeworks

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Bispecific Antibody Therapeutics: Technology Platforms

6. Drug Profiles

7. Key Insights 

8. Benchmark Analysis: Big Pharma Players

9. Partnerships and Collaborations

10. Contract Services for Bispecific Antibody Therapeutics

11. Clinical Trial Analysis

12. Case Study: Regulatory Guidelines for Bispecific Antibodies

13. Case Study: Promotional / Marketing Strategies

14. SWOT Analysis

 

15. Market Forecast and Opportunity Analysis

 

16. Concluding Remarks

 

17. Executive Insights

 

18. Appendix 1: Tabulated Data

 

19. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com